Wellington reports 19.8M EW shares (3.38%) in Schedule 13G/A
Wellington Management reports beneficial ownership of 19,826,483 shares of Edwards Lifesciences common stock, equal to 3.38% of the class.
Rhea-AI Filing Summary
Wellington Management reports beneficial ownership of 19,826,483 shares of Edwards Lifesciences common stock, equal to 3.38% of the class. The filing shows shared voting power of 18,601,111 shares and shared dispositive power of 19,826,483 shares, while sole voting and dispositive power are reported as zero. The securities are owned of record by clients of Wellington investment advisers.
The filing names the reporting entities (Wellington Management Group LLP; Wellington Group Holdings LLP; Wellington Investment Advisors Holdings LLP) and lists the Wellington investment advisers that control the client accounts. It also includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Positive
- Aggregated beneficial ownership disclosed: 19,826,483 shares (3.38%)
- Clear governance of holdings: shared voting power (18,601,111) and shared dispositive power documented
- Held in ordinary course: filing certifies shares are not held to influence control of the issuer
Negative
- None.
Insights
TL;DR: A sizable passive stake disclosed: 19.83M EW shares (3.38%), held in client accounts with shared voting influence.
The Schedule 13G/A reports aggregated beneficial ownership of 19,826,483 Edwards Lifesciences shares, representing 3.38% of the class, with 18,601,111 shares carrying shared voting power. This indicates the holdings are material enough to warrant disclosure but remain below the 5% threshold that often triggers additional investor-level identification. The filing clarifies ownership is of record by clients of Wellington advisers and includes the statutory certification that the positions are held in the ordinary course of business and not for control purposes, consistent with passive investor treatment.
TL;DR: Disclosure is routine and indicates shared control through client mandates, not an active control campaign.
The filing identifies Wellington entities as the reporting parties and lists the specific investment adviser affiliates that manage the client accounts. Reported shared voting and dispositive powers show Wellington exercises influence on behalf of clients rather than sole control. The certification in the filing confirms the positions were not acquired to influence issuer control, which aligns with a passive Schedule 13G disclosure rather than an activist intent.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of EW does the reported stake represent?
Was the stake acquired to influence control of Edwards Lifesciences?
AI-generated analysis. How Rhea-AI works. Not financial advice.